JPMHC 2020

Merck turns to contract manufacturers to help with Gardasil supply, plans 2023 plant openings
Merck turns to contract manufacturers to help with Gardasil supply, plans 2023 plant openings
Fierce Pharma
Merck
Ken Frazier
Pharma CEOs
JPMHC 2020
Gardasil
vaccines
drug manufacturing
Flag link:
After big year, RNAi drugmakers compete to prove what comes next
After big year, RNAi drugmakers compete to prove what comes next
BioPharma Dive
RNAi
JPMHC 2020
Alynylam
Arrowhead Pharmaceuticals
Dicerna Pharmaceuticals
Flag link:
The truth about JPM: Less is more
The truth about JPM: Less is more
Stat
JPMHC 2020
Flag link:
JPM: Biotech, VC execs on where the industry should look beyond cancer
JPM: Biotech, VC execs on where the industry should look beyond cancer
Fierce Biotech
oncology
cancer
Alzheimer's disease
diabetes
venture capital
JPMHC 2020
Flag link:
Celltrion plans to launch a biosimilar each year for next decade
Celltrion plans to launch a biosimilar each year for next decade
Pharmaforum
Celltrion
South Korea
biosimilars
JPMHC 2020
Flag link:
Eli Lilly targets quarterly deals of $1 billion-$5 billion in 2020: CFO
Eli Lilly targets quarterly deals of $1 billion-$5 billion in 2020: CFO
Reuters
Lilly
M&A
JPMHC 2020
Flag link:
BioMarin Considers $3 Million Price Tag for New Hemophilia Gene Therapy
BioMarin Considers $3 Million Price Tag for New Hemophilia Gene Therapy
Motley Fool
Biomarin
JPMHC 2020
drug pricing
valrox
hemophilia
Flag link:
Think JPM seemed slow this year? You're not alone—and here's why
Think JPM seemed slow this year? You're not alone—and here's why
Fierce Pharma
JPMHC 2020
M&A
Flag link:
JPM sound bites, vol. 1: Couch shopping, cool drones and 'smelling the turkey'
JPM sound bites, vol. 1: Couch shopping, cool drones and 'smelling the turkey'
Fierce Pharma
JPMHC 2020
Flag link:
JPM: Glaxo sees enormous Shingrix potential, but a supply gap still stands in the way
JPM: Glaxo sees enormous Shingrix potential, but a supply gap still stands in the way
Fierce Pharma
GSK
vaccines
Shingrix
shingles
drug shortages
JPMHC 2020
Flag link:
J.P. Morgan Trends: Digital Health Confusion, Tech, Drug Prices and Diversity
J.P. Morgan Trends: Digital Health Confusion, Tech, Drug Prices and Diversity
BioSpace
JPMHC 2020
M&A
diversity
digital health
technology
drug pricing
Flag link:
After IPO, BioNTech nabs cell therapy startup Neon Therapeutics
After IPO, BioNTech nabs cell therapy startup Neon Therapeutics
Fierce Biotech
JPMHC 2020
BioNTech
Neon Therapeutics
M&A
Flag link:
GSK, Pfizer contradict on the future of consumer health JV — report
GSK, Pfizer contradict on the future of consumer health JV — report
Endpoints
GSK
Pfizer
consumer health
JPMHC 2020
Flag link:
JPM: New Novartis pharma chief rethinks its drug-launch formula
JPM: New Novartis pharma chief rethinks its drug-launch formula
Fierce Pharma
Novartis
Pharma CEOs
Vas Narasimhan
drug launches
JPMHC 2020
Flag link:
JPM: Mayo Clinic, nference launch ambitious data platform initiative
JPM: Mayo Clinic, nference launch ambitious data platform initiative
Fierce Biotech
JPMHC 2020
Mayo Clinica
nference
data analytics
healthcare data
analytics
Flag link:
JPM: Already prepping for Alzheimer's launch, Biogen scouts 'top talent' and talks pricing
JPM: Already prepping for Alzheimer's launch, Biogen scouts 'top talent' and talks pricing
Fierce Pharma
Biogen
Alzheimer's disease
drug pricing
aducanumab
JPMHC 2020
Flag link:
JPM: Alnylam CEO looks to action-packed 2020 on the heels of Givlaari approval
JPM: Alnylam CEO looks to action-packed 2020 on the heels of Givlaari approval
Fierce Pharma
Alnylam
RNAi
Givlaari
John Maraganore
JPMHC 2020
Flag link:
JPM Monday roundup: No deals, but drug-pricing startup causes the biggest noise
JPM Monday roundup: No deals, but drug-pricing startup causes the biggest noise
Fierce Biotech
JPMHC 2020
M&A
Gilead Sciences
Bristol-Myers Squibb
Flag link:
GSK’s CEO Walmsley aiming for six new approvals in 2020
GSK’s CEO Walmsley aiming for six new approvals in 2020
Pharmaforum
GSK
Pharma CEOs
Emma Walmsley
JPMHC 2020
Zejula
Trelegy
daprodustat
belantamab mafodotin
Flag link:
JPM kickoff: Gilead's deal ideal, Novartis' image-polishing, Teva's shutdown tally and one CEO's word on another
JPM kickoff: Gilead's deal ideal, Novartis' image-polishing, Teva's shutdown tally and one CEO's word on another
Fierce Pharma
JPMHC 2020
Teva Pharmaceuticals
Novartis
Gilead Sciences
M&A
Pharma CEOs
Flag link:

Pages